COMMUNIQUÉS West-GlobeNewswire

CymaBay Reports Second Quarter 2019 Financial Results and Provides Corporate Update
07/08/2019
Conference call and webcast today at 4:30p.m. ET NEWARK, Calif., Aug. 07, 2019 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies [...]
Rubius Therapeutics to Announce Second Quarter 2019 Financial Results
07/08/2019
CAMBRIDGE, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is generating red blood cells and bioengineering them into an entirely new [...]
Nephros Reports Second Quarter Financial Results
07/08/2019
Product Revenue up 88% over Q2 2018; Reiterates 2019 Full-Year Revenue Guidance SOUTH ORANGE, N.J., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Nephros, Inc. (OTCQB:NEPH), a commercial stage company that develops and sells high [...]
DBV Technologies Submits Biologics License Application to U.S. Food and Drug Administration for Viaskin Peanut for the Treatment of Peanut Allergy
07/08/2019
Montrouge, France, August 7, 2019 DBV Technologies Submits Biologics License Application to U.S. Food and Drug Administration for Viaskin Peanut for the Treatment of Peanut Allergy DBV Technologies (Euronext: DBV - ISIN [...]
DBV Technologies soumet la demande de licence biologique à la FDA pour Viaskin Peanut dans le traitement de l’allergie à l’arachide
07/08/2019
Montrouge, France, le 7 août (22 h 00 CEST) 2019 DBV Technologies soumet la demande de licence biologique à la FDA pour Viaskin Peanut dans le traitement de l’allergie à l’arachide DBV Technologies (Euronext : DBV - [...]
Zosano Pharma to Host Conference Call on Second Quarter 2019 Financial Results and Provide Operational Update
07/08/2019
FREMONT, Calif., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast on Wednesday, [...]
Aravive Reports Second Quarter 2019 Financial Results and Provides Recent Corporate Updates
07/08/2019
HOUSTON, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company developing treatments designed to halt the progression of life-threatening diseases, including cancer [...]
miRagen Reports Second Quarter 2019 Results; Regains Global Rights to MRG-110 and Announces Corporate Restructuring
07/08/2019
miRagen to regain global rights to MRG-110 after Servier provides notice of portfolio realignment; expects to announce Phase 1 data during the second half of 2019 Company anticipates reporting primary endpoint data from [...]
Kezar Life Sciences Reports Second Quarter 2019 Financial Results and Provides Business Update
07/08/2019
Promising data reported from the Phase 1b portion of MISSION, a first-in-patient study of KZR-616; Phase 2 portion of MISSION in LN patients has been initiated Phase 2 PRESIDIO and MARINA trials have been initiated [...]
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2019 Financial Results
07/08/2019
REDWOOD CITY, Calif., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, [...]
Constellation Pharmaceuticals Announces Second-Quarter and Six-Month 2019 Financial Results
07/08/2019
Data presented at ASCO and EHA suggest potential disease-modifying activity of CPI-0610 across the spectrum of myelofibrosis (MF) parameters, with multiple potential pathways for approval The EZH2 franchise continues to [...]
GBT Reports Recent Business Progress and Second Quarter 2019 Financial Results
07/08/2019
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported recent business progress and financial results for the second quarter ended June 30, 2019 [...]
OpGen Reports Second Quarter 2019 Financial Results and Provides Business Update
07/08/2019
Revenue up 28% Quarter-over-Quarter Progression of 510(k) submission to the FDA for clearance of the Acuitas® AMR Gene Panel test for bacterial isolates Conference call to be held at 4:30 p.m. Eastern Time today [...]
Sarepta Therapeutics Announces Second Quarter 2019 Financial Results and Recent Corporate Developments
07/08/2019
CAMBRIDGE, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported financial results for the second quarter of 2019 [...]
TransMedics Reports Second Quarter 2019 Financial Results
07/08/2019
ANDOVER, Mass., Aug. 07, 2019 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, [...]
Sunesis Pharmaceuticals Reports Second Quarter 2019 Financial Results and Recent Highlights
07/08/2019
Sunesis to Host Conference Call Today at 4:30 PM Eastern Time SOUTH SAN FRANCISCO, Calif., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the quarter [...]
Corvus Pharmaceuticals to Present at the 2019 Wedbush Healthcare Conference
07/08/2019
BURLINGAME, Calif., Aug. 07, 2019 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted [...]
Ovid Therapeutics Reports Second Quarter 2019 Financial Results and Highlights Recent Progress
07/08/2019
Phase 3 NEPTUNE Trial of OV101 in Angelman Syndrome on Track to Enroll the First Patients in the Third Quarter of 2019 Regulatory Authorities in the U.S. and Germany agree that NEPTUNE, if positive, could support the [...]
CohBar Reports Second Quarter 2019 Financial Results and Business Update
07/08/2019
Company to host conference call and webcast today, August 7 th , at 5:00 p.m. EDT MENLO PARK, Calif., Aug. 07, 2019 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing [...]

Pages